Plasma lactoferrin reflects granulocyte activation via complement in burn patients.
Complement activation and neutropenia have been observed in thermally injured animals. In burn patients, granulocyte chemotaxis and morphological loss of specific granules occur. We conjectured that complement is activated in humans and, in turn, induces granulocytes to secrete lactoferrin (LF), a marker of granulocyte activation. Twenty burn patients were evaluated for absolute granulocyte count (AGC), plasma levels of anaphylatoxins (C3a, C4a, C5a), and lactoferrin. The AGC directly correlated with the extent of the burn on day 1. Similarly, plasma LF on day 1 correlated with the percent burn. Those with greater than 30% burn had plasma LF between 10 and 40 micrograms/ml (normal LF = 1.5 +/- 1.8 micrograms/ml). In five patients without further complications followed serially, plasma LF did not return to normal until 2 to 5 weeks. In all patients, there was evidence of complement activation; C4a ranged between 283 and 13,064 ng/ml and C3a between 19 and 852 ng/ml. In some patients, C5a was detectable, but the values correlated inversely with the extent of burn. On the other hand C3a and C4a levels did not correlate with the extent of burn but threefold to fivefold rises of C3a levels on days 7 and 9 predicted gram-negative sepsis. Although plasma LF did not predict sepsis, levels greater than 12 micrograms/ml on day 1 heralded the onset of neutropenia on day 3 in 60% of patients with 30% burn. Six of 20 patients developed pulmonary radiographic changes and, in five of the six, the changes occurred by day 3. Plasma LF in all six patients on day 1 was greater than 17 micrograms/ml. In two patients with greater than 50% burn, depletion of granulocyte LF was demonstrated histochemically. These studies indicate that complement is activated in burn patients, which is associated with granulocyte secretion. Measurement of plasma anaphylatoxins and LF may serve as useful aides in clinical management of these patients.
D000328:Adult; D002056:Burns / Q000097:blood*; D003167:Complement Activation; D003176:Complement C3 / Q000097:blood; D015926:Complement C3a; D003181:Complement C4 / Q000097:blood; D015934:Complement C4a; D003182:Complement C5 / Q000097:blood; D015936:Complement C5a; D005260:Female; D006098:Granulocytes / Q000378:metabolism*; D006801:Humans; D007781:Lactoferrin / Q000097:blood*; D007782:Lactoglobulins / Q000097:blood*; D008297:Male
D003176:Complement C3; D003181:Complement C4; D003182:Complement C5; D007782:Lactoglobulins; D015926:Complement C3a; D015934:Complement C4a; D015936:Complement C5a; D007781:Lactoferrin